{"owner": "ArrayExpress Uploader", "pop_total": 0, "species": "mouse", "factors": [{"GSM77529": {"GENOTYPE": "RARaKO", "TREATMENT": "EtOH + cycloheximide"}}, {"GSM775292": {"GENOTYPE": "RARaKO", "TREATMENT": "atRA + cycloheximide"}}, {"GSM775293": {"GENOTYPE": "WT", "TREATMENT": "EtOH + cycloheximide"}}, {"GSM775294": {"GENOTYPE": "WT", "TREATMENT": "atRA + cycloheximide"}}, {"GSM77529": {"GENOTYPE": "RARaKO", "TREATMENT": "EtOH + cycloheximide"}}, {"GSM775292": {"GENOTYPE": "RARaKO", "TREATMENT": "atRA + cycloheximide"}}, {"GSM775293": {"GENOTYPE": "WT", "TREATMENT": "EtOH + cycloheximide"}}, {"GSM775294": {"GENOTYPE": "WT", "TREATMENT": "atRA + cycloheximide"}}, {"GSM77529": {"GENOTYPE": "RARaKO", "TREATMENT": "EtOH + cycloheximide"}}, {"GSM775292": {"GENOTYPE": "RARaKO", "TREATMENT": "atRA + cycloheximide"}}, {"GSM775293": {"GENOTYPE": "WT", "TREATMENT": "EtOH + cycloheximide"}}, {"GSM775294": {"GENOTYPE": "WT", "TREATMENT": "atRA + cycloheximide"}}], "id": 6580, "ownerprofile_id": "arrayexpress_sid", "platform": 6, "summary_wrapped": "Retinoic acid receptors (RARs) \u03b1, \u03b2 and \u03b3 are key regulators of embryonic development. Hematopoietic differentiation is regulated by...", "geo_gse_id": "E-GEOD-31280", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 2, "sample_count": 12, "tags": ["leukemia", "protein", "teratocarcinoma"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "transcript-level-in-f9-teratocarcinoma-wt-and-rara", "geo_id_plat": "E-GEOD-31280_A-AFFY-45", "name": "Transcript level in F9 teratocarcinoma WT and RARalpha knockout in presence and absence of all-trans retinoic acid", "created": "Nov.11, 2014", "summary": "Retinoic acid receptors (RARs) \u03b1, \u03b2 and \u03b3 are key regulators of embryonic development. Hematopoietic differentiation is regulated by RAR\u03b1, and several types of leukemia show aberrant RAR\u03b1 activity. We demonstrate that RAR\u03b1 plays an important role in cellular memory and imprinting by regulating the CpG methylation status of specific promoter regions. We used microarrays to identify genes, which display differential expression in F9 RARalpha knockout (RARaKO) cells relative to F9 wt cells. F9 teratocarcinoma cells (WT and RARaKO) were treated for 8 hours with either vehicle (EtOH) or all-trans Retinoic Acid (atRA) in the presence of the protein synthesis inhibitor Cycloheximide", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-31280", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-31280/samples/"}